Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of golidocitinib versus investigator's choice in relapsed or refractory peripheral T-cell lymphoma
CTR20240028Phase 3Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started May 2024; status: active.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20240028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240028.